

Abramson Cancer Center Translational Centers of Excellence (TCE)

Thoracic Oncology (Lung Cancer) TCE

Directors: Steven Albelda, MD (Translational); Corey Langer, MD (Clinical)

Project / Database Manager: Christiana Davis, MD

List of Publications (The authors benefited from the TCE's funding, services, resources and collaborations)

1. Aggarwal C, Davis C, et.al. Influence of TP53 and Other Concomitant Mutations on Survival in Patients with EGFR-mutant Advanced NSCLC (Manuscript in preparation)
2. Bagley SJ, Kothari S, Aggarwal C, Bauml J, Alley E, Evans TL, Kosteva J, Ciunci C, Gabriel P, Thompson J, Stonehouse-Lee S, Sherry VE, Gilbert E, Sandy BE, Mutale F, DiLullo G, Cohen R, Vachani A, Langer CJ. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. *Lung Cancer* 2017, 106: 1–7
3. Beatty, G.L., Haas, A.R., Maus M.V., Torigian, D.A., Soulen, M.C., Piesa, G., Chew, A., Zhao, Y., Levine B.L., Albelda, S.M., Kalos, M., June, C.H. Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies. *Cancer Immunology Research*, 2:112-120. 2014. PMID: PMC3932715
4. Wang, L.C., Lo, A., Scholler, J., Sun, Majumdar, R.S., Kapoor, V., Antziz, M., Cotner, C., Johnson, L.A. Durham, A.C., Solomides C.C., June, C.H., Pure, E., Albelda, S.M., Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity Without Severe Toxicity. *Cancer Immunology Research*, 2:154-166, 2014. PMID: PMC4007316
5. Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM. Multifactorial T cell Hypofunction that is Reversible Can Limit the Efficacy of Chimeric Antibody Receptor-transduced Human T cells in Solid Tumors. *Clinical Cancer Res* 20:4262-4273. 2014. PMID: PMC4134701
6. Eruslanov EB, Bhojnagarwala, P.S., Quatromoni, J.G., Stephen, T.L., Ranganathan, A, Deshpande, C., Akimova, T, Vachani, A., Litzky, L., Hancock W., Conejo-Garcia, J.R., Feldman, M., Albelda S.M., Singhal, S. Tumor-Associated Neutrophils Stimulate T Cell Responses in Early Stage Human Lung Cancer, *J. Clinical Investigation*, 124:5466-80. 2014. PMID: PMC4348966
7. Beatty GL, Moon EK. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. *Oncimmunology*. 2014 Dec 21; 3(11):e970027.
8. Albelda S.M., Thorne S.H. Giving Oncolytic Viruses more BiTE. *Molecular Therapy* 22:6-8, 2014. PMID: PMC3978795.
9. Quatromoni J, Singhal S, Bhojnagarwala P, Hancock WW, Albelda SM, Eruslanov E. An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells. *J Leukoc Biol*. 97:201-9, 2015. PMID: 25359999
10. Wang E, Wang LC, Tsai CY, Bhoj V, Gershenson Z, Moon E, Newick K, Sun J, Lo A, Baradet T, Feldman MD, Barrett D, Pure E, Albelda S, Milone MC. Generation of potent T-cell immunotherapy for cancer using DAPI2-based, multichain, chimeric immunoreceptors. *Cancer Immunol Res*. 3:815-26. 2015. PMID: 4490943.
11. Lo A, Wang LC, Scholler J, Monslow J, Avery D, Newick K, O'Brien S, Evans RA, Bajor DL, Clendenin C, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, Pure E. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. *Cancer Res*. 75:2800-10. 2015. PMID: PMC4506263.
12. Fridlender ZG, Albelda SM, Granot Z. Promoting metastasis: neutrophils and T cells join forces. *Cell Res*. 25:765-6, 2015. PMID: PMC4493274.
13. Moon EK, Ranganathan R, Eruslanov E, Kim S, Newick K, O'Brien S, Lo A, Liu X, Zhao Y, Albelda SM. Blockade of Programmed Death 1 Augments the Ability of Human T cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. *Clin Cancer Res*. 22: 436-447, 2016 PMID: PMC4715990.
14. Newick K, O'Brien S, Sun J, Kapoor V, Maceyko S, Lo A, Pure E, Moon E, Albelda SM. Augmentation of CAR T cell trafficking and antitumor efficacy by blocking protein kinase A (PKA) localization. *Cancer Immunology Research*, 2016 6:541-51.
15. Newick K, Moon E, Albelda SM. CAR T Cell Therapy For Solid Tumors, *Molec Therapy Oncolytics*, 2016 Apr 13;3:16006.
16. Serman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz SI, Sun J, Heitjan D, Hwang, WT, Litzky L, Yearley JH, Tan KS, Papasavvas E, Kennedy P, Montaner L, Cengel KA, Simone CB, Culligan M, Langer CJ, Albelda SM. Pilot and Feasibility Trial of Immuno-Gene Therapy of Malignant Mesothelioma

Using Intrapleural Delivery of Adenovirus-Interferon-alpha Combined with Chemotherapy. *Clinical Cancer Research*, 2016 22:3791-800.

17. Singhal S, Bhojnagarwala PS, O'Brien S, Moon EK, Garfall AL, Rao A, Quatromoni JG, Stephen TL, Litzky L, Deshpande C, Feldman M, Hancock WW, Conejo-Garcia JR, Albelda SM, Eruslanov EB. Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen Presenting Cell Features (Hybrid TANs) in Early-Stage Human Lung Cancer. *Cancer Cell*, 2016, 30:120-35.
18. Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, , Newick K, Lo A, June CH, Zhao Y, Moon EK. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. *Cancer Res*. 2016; 76: 1578-90.
19. Newick K, O'Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. *Annual Review of Medicine* 2016, in press.